Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress [Yahoo! Finance]
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy [Yahoo! Finance]
Nuvation Bio (NUVB) had its price target lowered by UBS Group AG from $10.00 to $7.00. They now have a "neutral" rating on the stock.